By targeting cell surface receptors such as EGFR, VEGFR, HER2, and MET, and their downstream signaling pathways, it is possible to inhibit HNSCC cell proliferation, invasion, and migration. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.